Comparison of some practical sampling strategies for population pharmacokinetic studies

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 2, 1996, Pages 245-263

  Jonsson, E Niclas ^a   Wade, Janet R ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

NONMEM; population analysis; sampling design; study design

Indexed keywords

ARTICLE; DATA ANALYSIS; MODEL; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; SAMPLING; SIMULATION;

EID: 0029776497     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353491     Document Type: Article

References (16)

1. L. Aarons. Sparse data analysis. Eur. J. Drug Metab. Pharmacokin. 18:97-100 (1993).
2. L. B. Sheiner and S. L. Beal. Evaluation of methods for estimating population pharmacokinetic parameters III. Mono exponential model: Clinical pharmacokinetic data. J. Pharmacokin. Biopharm. 11:303-319 (1983).
3. M. K. Al-Banna, A. W. Kelman, and B. Whiting. Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokin. Biopharm. 18:347-360 (1990).
4. Y. Hashimoto and L. B. Sheiner. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J. Pharmacokin. Biopharm. 19:333-333 (1991).
5. D. Z. D'Argenio. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokin. Biopharm. 9:739-756 (1981).
6. F. Mentré. Optimal design in population analysis including Bayesian aspects. In PAGE, First meeting, Paris, France, 1993.
7. A. Grahnén, M. Hammarlund, and T. Lundqvist. Implications of intraindividual variability in bioavailability studies of furosemide. Eur. J. Clin. Pharmacol. 27:595-602 (1984).
8. M. O. Karlsson and A. Lindberg-Freijs. Comparison of methods to calculate cyclosporine: A bioavailability from consecutive oral and intravenous doses. J. Pharmacokin. Biopharm. 18:293-311 (1990).
9. M. Rowland. Intra-individual variability in pharmacokinetics. In D. D. Breimer (ed.), Towards Better Safety of Drugs and Pharmaceutical Products, Elsevier, North-Holland, 1980.
10. J. R. Wade, A. W. Kelman, C. A. Howie, and B. Whiting. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J. Pharmacokin. Biopharm. 21:209-222 (1993).
11. S. L. Beal and L. B. Sheiner. NONMEM Users Guide - Part VII. NONMEM Project Group, University of California, San Francisco, CA, 1992.
12. L. B. Sheiner and S. B. Beal. Some suggestions for measuring predictive performance. J. Pharmacokin. Biopharm. 9:503-512 (1981).
13. J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511-528 (1992).
14. M. O. Karlsson and L. B. Sheiner. The importance of modelling the inter-occasion variability in population pharmacokinetic studies. J. Pharmacokin. Biopharm. 21:735-750 (1993).
15. A. J. Boeckmann, L. B. Sheiner, and S. L. Beal. NONMEM Users Guide - Part V. NONMEM Project Group, University of California, San Francisco, CA, 1992.
16. P. O. Maitre, M. Buhrer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J. Pharmacokin. Biopharm. 19:377-384 (1991).